Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis

Allergol Int. 2020 Jul;69(3):483-484. doi: 10.1016/j.alit.2020.03.001. Epub 2020 Mar 27.

Authors

Stefania Colantuono¹, Chiara Pellicano¹, Giorgia Leodori¹, Francesco Cilia², Marco Francone², Marcella Visentini³

Affiliations

¹ Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
² Department of Radiological, Oncological and Pathological Sciences, Sapienza University, Rome, Italy.
³ Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. Electronic address: marcella.visentini@uniroma1.it.

PMID: 32224025
DOI: 10.1016/j.alit.2020.03.001

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Eosinophilia / complications
Eosinophilia / diagnosis
Eosinophilia / drug therapy*
Granulomatosis with Polyangiitis / complications
Granulomatosis with Polyangiitis / diagnosis
Granulomatosis with Polyangiitis / drug therapy*
Humans
Male
Myocarditis / complications
Myocarditis / diagnosis
Myocarditis / drug therapy*
Treatment Outcome
Young Adult

Substances

Antibodies, Monoclonal, Humanized
benralizumab